Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer

Expert Review of Molecular Diagnostics

Volumn 16, Issue 12, 2016, Pages 1251-1257

  Hsiue, Emily Han Chung ^a   Lee, Jih Hsiang ^a,b   Lin, Chia Chi ^a,b   Yang, James Chih Hsin ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

amplification refractory mutation system; EGFR; gefitinib; non small cell lung cancer; Scorpions

Indexed keywords

AFATINIB; CARBOPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OSIMERTINIB; PACLITAXEL; DIAGNOSTIC KIT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; EXON; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LUNG ADENOCARCINOMA; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; POLYMERASE CHAIN REACTION SYSTEM; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW (TOPIC); BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC KIT; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENETICS; LUNG NEOPLASMS; MALIGNANT PLEURA EFFUSION; MUTATION; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; STANDARDS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PLEURAL EFFUSION, MALIGNANT; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REAGENT KITS, DIAGNOSTIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84992529753     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2016.1248414     Document Type: Article

References (48)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139.•• This is one of the two studies indicating the correlation between the EGFR mutations and sensitivity to gefitinib.
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.•• This is one of the two studies indicating the correlation between the EGFR mutations and sensitivity to gefitinib.
3. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.• This is one of the two randomized studies that validated the clinical utility of the therascreen® EGFR RGQ PCR kit.
5. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128.
7. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma:a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26(34):5589–5595.
8. Kazandjian D, Blumenthal GM, Yuan W, et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 2016;22(6):1307–1312.
9. Hiley CT, Le Quesne J, Santis G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016;388(10048):1002–1011.
10. Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer:a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79–89.
11. Pao W, Ladanyi M., Epidermal growth factor receptor mutation testing in lung cancer:searching for the ideal method. Clin Cancer Res. 2007;13(17):4954–4955.
12. QIAGEN Manchester Ltd. Therascreen EGFR RGQ PCR kit handbook. Manchester:QIAGEN Manchester Ltd.; 2013.
13. QIAGEN Manchester Ltd. Therascreen EGFR RGQ PCR Kit instructions for use (Handbook). Manchester:QIAGEN Manchester Ltd.; 2015.
14. Summary of safe and effectiveness data:therascreen® EGFR RGQ PCR kit [Internet]. US Food and Drug Administration; 2013 [cited 2016 Aug 2]. Available from:http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120022b.pdf
15. Kaneda T, Hata A, Tomioka H, et al. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Lung Cancer. 2014;86(2):213–218.
16. Wang S, Wang Z. EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features:a meta-analysis. Int J Clin Exp Med. 2014;7(8):1967–1978.
17. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503–2516.
18. Whitcombe D, Theaker J, Guy SP, et al. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol. 1999;17(8):804–807.
19. Douillard J, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients:a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55–62.• This is one of the two randomized studies that validated the clinical utility of the therascreen® EGFR RGQ PCR kit.
20. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334.
21. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6):an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222.
22. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final OS results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874.
23. Westwood M, Joore M, Whiting P, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer:a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(32):1–192.
24. Han J-Y, Park K, Kim SW, et al. First-SIGNAL:first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128.
25. Benlloch S, Botero ML, Beltran-Alamillo J, et al. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer:retrospective testing of specimens from the EURTAC trial. PLoS One. 2014;9(2):e89518.
26. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
27. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742.
28. Summary of safety and effectiveness data:cobas EGFR mutation test [Internet]. Food and Drug Administration; 2013 [cited 2016 Aug 2]. Available from:http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120019b.pdf
29. Highlights of prescriibing information:tagrisso (Osimertinib) [Internet]. Food and Drug Administration; 2015 [cited 2016 Aug 1]. Available from:http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf
30. Lopez-Rios F, Angulo B, Gomez B, et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol. 2013;66(5):381–385.
31. Kimura H, Ohira T, Uchida O, et al. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer. 2014;83(3):329–333.
32. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281(5375):363–365.
33. Cushman-Vokoun AM, Crowley AM, Rapp SA, et al. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer. Am J Clin Pathol. 2013;140(1):7–19.
34. Diaz LAJ, Bardelli A. Liquid biopsies:genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586.
35. Douillard J-Y, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC:circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345–1353.
36. Reck M, Hagiwara K, Han B, et al. ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC:the ASSESS study. J Thorac Oncol. 2016;11(10):1682–1689.
37. Approved drugs–cobas EGFR mutation test v2. Center for Drug Evaluation and Research, Research; 2016 [cited 2016 Aug 1]. Available from:http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540.htm
38. Liu D, Lu Y, Hu Z, et al. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma. PLoS One. 2014;9(2):e89946.
39. Liu Y, Liu B, Li X-Y, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung Cancer patients. J Exp Clin Cancer Res. 2011;30(1):111–111.
40. Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer. 2006;95(10):1390–1395.
41. Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 2006;97(7):642–648.
42. Watanabe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014;9(2):189–194.
43. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations:a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838.
44. Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66(16):7854–7858.
45. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433–440.
46. Thomas A, Rajan A, Lopez-Chavez A, et al. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol. 2013;24(3):577–585.
47. Decatris MP, Farrugia D, O’Byrne KJ. Clinician perspective on molecular profiling of non-small-cell lung cancer. J Clin Oncol. 2016;34(8):884–886.
48. Evans BJ, Burke W, Jarvik GP. The FDA and genomic tests–getting regulation right. N Engl J Med. 2015;372(23):2258–2264.